117 results about "Mouse Testis" patented technology

The invention relates to the technical field of biology, in particular to multifunctional belly-expanding hippocampal peptide as well as a preparation method and application thereof. Comprising a polypeptide with an amino acid sequence as shown in SEQ ID NO.1. The hippocampus antioxidative peptide is prepared by adopting an ultrahigh pressure pretreatment and enzymolysis technology, the adopted extraction process is simple in route, and the time and the production cost are effectively saved; an animal model is utilized to prove the anti-oxidation effect and the effect of improving male reproductive disorder and testis injury of the multifunctional belly-expanding hippocampal peptide; and on the basis, a novel peptide fragment with high activity, no toxicity and no sensitization is obtained.

The invention discloses construction of a Guangdong small-ear spotted pig spermatogonial stem cell in-vitro culture system and screening of surface markers, and belongs to the technical field of cell culture.The technical scheme includes that testis are broken firstly, then enzyme digestion, density gradient centrifugal purification and differential adherent purification are conducted, and purified spermatogonial stem cells are obtained; inoculating the obtained spermatogonial stem cells to feeder layer cells and culturing in a culture medium; the culture medium is a DMEM culture medium added with FBS and growth factors; the mass fraction of the FBS in the DMEM culture medium is 8-12%, an enzyme digestion method, a density gradient centrifugation method and a differential adhesion method are combined for application, the Guangdong small-ear spotted pig spermatogonia stem cells with certain purity are obtained, cells enriched and purified in vitro can proliferate massively, and an in-vitro culture system of the Guangdong small-ear spotted pig spermatogonia stem cells is established.

The invention relates to the technical field of biological medicine, and discloses rapamycin-loaded microemulsion gel as well as a preparation method and application thereof. The preparation method of the microemulsion gel comprises the following steps: dissolving N, N-dimethyl octadecyl carboxymethyl chitosan in a water phase, then adding an oil phase, a cosurfactant and rapamycin, and stirring to obtain rapamycin-loaded microemulsion; the preparation method comprises the following steps: dissolving a high polymer material in a PBS solution, heating until the high polymer material is completely dissolved, then adding dopamine, stirring for reaction, and finally dialyzing and freeze-drying to obtain the adhesive. And adding a gel matrix containing a thickening agent and an adhesive into the microemulsion, and stirring to obtain the rapamycin-loaded microemulsion gel. According to the prepared microemulsion gel, transdermal drug delivery of hydrophobic drugs is achieved, testis are coated with the microemulsion gel loaded with rapamycin, the blocking effect of damp-heat stress on differentiation and development of testis interstitial cells can be relieved, and the functionality of a male reproduction endocrine system is recovered.

The invention relates to a real-time testis rare sperm auxiliary identification method and device which are used for testis incision sperm extraction under a microscope, and the method comprises the following steps: obtaining first real-time image dynamic data; inputting the first real-time image dynamic data to a rare testis sperm auxiliary identification model to obtain rare testis sperm data; and updating the first real-time image dynamic data based on the rare testis sperm data to obtain second real-time image dynamic data. The method has the advantages that due to the fact that the auxiliary identification model for the rare sperms of the testis is high in response speed, the first real-time image dynamic data can be rapidly identified and updated, and the problems of labeling dislocation, repeated identification and the like cannot occur.

The invention relates to the technical field of cell culture media, in particular to a sheep testis somatic cell culture medium and a culture method.The sheep testis somatic cell culture medium is prepared from, by weight, 10-15 parts of MEMS alpha, 4-7 parts of KSR, 2-4 parts of sodium chloride, 3-5 parts of recombinant human transferrin, 1-3 parts of ferric citrate, 2-4 parts of L-glutamine, 5-10 parts of water and 4-7 parts of hydroxyapatite. According to the cell culture medium, MEM and KSR are adopted as matrix raw materials, sodium chloride and other auxiliaries are added, the hydroxyapatite agent is matched, the performance change of the cell culture medium on the survival rate and the survival amount of testicular somatic cells is enhanced, meanwhile, hydroxyapatite serves as a matrix of the hydroxyapatite agent, the performance of the cell culture medium is improved through a specific modification solution, and the cell culture medium is prepared. And the function of hydroxyapatite blended kaolin in the system is optimized, so that the functional effect of the cell culture medium is enhanced, and the performance of the product is further improved.

This invention provides a biomarker for spermatogenesis disorders and its application, wherein the biomarker is the MNDA molecule. This application characterizes the functional abnormalities or spermatogenesis disorders of Sertoli cells by detecting the expression level of MNDA molecules on cells in testicular tissue sections, and can therefore be used for the clinical diagnosis of non-obstructive azoospermia.

The invention discloses application of combination of ginsenoside Rb1 and luteolin in prevention and treatment of male reproductive toxicity caused by organophosphorus pesticides, and belongs to the field of medicines. A high-toxicity organophosphorus pesticide glyphosate is used as a representative, the reproductive toxicity effect of the glyphosate on male mice and the relieving effect of the ginsenoside Rb1 and the composition of the ginsenoside Rb1 and the luteolin on the male reproductive toxicity of the glyphosate are observed through tests, and the result shows that the ginsenoside Rb1 and the luteolin composition have the effect of inhibiting the reproductive toxicity of the glyphosate. The ginsenoside Rb1 and the composition of the ginsenoside Rb1 and the luteolin have a remarkable relieving effect on male reproductive toxic diseases caused by organophosphorus pesticides, wherein the male reproductive toxic diseases comprise testis diseases and sperm malformation rate increase, and antioxidant index GSH decrease and T-SOD increase caused by the organophosphorus pesticides. Effective drugs and treatment strategies are provided for preventing and treating organophosphorus pesticide induced male reproductive toxicity and diseases induced by organophosphorus pesticide induced male reproductive toxicity.

This invention relates to the finding that testis development related protein (TDRP; also termed Immuno-moodulin or Imood herein) is a circulatory anxiogenic factor that modulates anxiety-like behaviour in mammalian models through the regulation of the immune system. Methods of treatment of mental disorders, such as anxiety, and TDRP antagonists for use in such methods are provided. Methods of diagnosing or monitoring a mental disorder in an individual by determining levels of TDRP in a sample and methods of screening for compounds that reduce levels of TDRP are provided.

The application belongs to the technical field of biological pharmacy, and particularly relates to a bovine-derived mouse anti-Brucella antibody and a preparation method and application thereof. A bovine-derived mouse anti-Brucella antibody is prepared by synthesizing a tandem epitope protein of Brucella OMP25 proteins of bovine species, sheep testis species and canine species, immunizing mice, preparing a monoclonal antibody, cloning CDR fragments in Hv and Lv regions of the antibody to corresponding positions of bovine-derived IgG, and then performing overall mutation modification on the recombinant IgG to perform bovine-derived modification. The bovine-derived mouse anti-Brucella antibody preparation has good immunogenicity and protection effect, and can block and inhibit the propagation and spread of Brucella of bovine species, canine species and sheep testis species in an animal body.

The invention discloses a reagent for editing a pig INSL3 gene and application of the reagent. The reagent for editing the pig INSL3 gene contains an INSL3-sgRNA A and an INSL3-sgRNA B, wherein the INSL3-sgRNA A and the INSL3-sgRNA The target sequence of the INSL3-sgRNA A is as shown in SEQ ID No.5; the target sequence of the INSL3-sgRNA B is shown in SEQ ID No. 6. Experiments prove that the INSL3-sgRNA A and the INSL3-sgRNA B are combined with a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 system, so that the pig INSL3 gene can be efficiently edited, and the editing efficiency of the INSL3 gene of pig testicular cells and the editing efficiency of the INSL3 gene of pig fetal fibroblasts can reach 8.47% and 11.45% respectively. The invention has important significance on the function research of the INSL3 gene of pig cells or individuals and the breeding of pig genetic disease resistance.

Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

The invention discloses a pilose antler active peptide and application thereof in anti-inflammation, anti-oxidation and anti-aging, and belongs to the technical field of biology. According to the invention, the brand-new active peptide SPLASDLDL screened out from pilose antler for the first time is utilized, and competitive inhibition on TNFR1 is realized through the characteristic that the brand-new active peptide SPLASDLDL is specifically combined with a TNFR1 receptor. A constructed sertoli cell senescence model proves that the polypeptide has anti-inflammatory, anti-oxidation and anti-senescence effects. The invention successfully solves the technical problem that in the prior art, the competitive inhibition TNFR1 targeting peptide cannot be found from pilose antler and the action mechanism of the TNFR1 targeting peptide cannot be clarified, and provides the action mechanism and scientific basis for developing novel anti-inflammatory and anti-aging drugs derived from natural products.

The invention discloses application of exosome-like nanoparticles derived from fructus lycii to preparation of a medicine for preventing or treating oligospermia and / or asthenospermia. Sterile, stable and high-purity fructus lycii exosome-like nanoparticles (LBELNs) are obtained by adopting a differential centrifugation-suction filtration-ultra-high-speed centrifugation method, the physiological efficacy of the LBELNs is researched, and it is found that the LBELNs can significantly improve the oligoasthenospermia disease activity index of male mice induced by cyclophosphamide (CTX); the sperm quantity is obviously increased, the sperm malformation is improved, the sperm motility is improved, and the sex hormone level is recovered. The LBELNs can effectively relieve spermatogenic dysfunction of testicular tissues, the sperm differentiation and formation process is obviously improved, the total number of sperms is increased, and the treatment effect is more obvious along with increase of the dosage of the LBELNs. The invention has potential in preparation of drugs for preventing or treating oligoasthenospermia, and provides a new strategy and treatment method for treating oligoasthenospermia.

The invention relates to the technical field of lion-head goose breeding, in particular to a method for screening and identifying genes related to lion-head goose sperm motility regulation and control, which comprises the following steps: dividing healthy lion-head male geese in a breeding period into a high sperm motility group and a low sperm motility group according to sperm motility, collecting two groups of testicular tissues and sperm samples, and preserving the testicular tissues at low temperature for molecular detection; performing transcriptome sequencing on the testicular tissue to obtain mRNA and non-coding RNA expression data; screening two groups of nucleic acid molecules with significant differential expression, and determining candidate genes through functional enrichment analysis of reproductive development related biological pathways; and verifying the authenticity of the expression difference of the candidate gene through fluorescent quantitative PCR, and finally determining the target gene. According to the method, related data are obtained through sequencing, the candidate genes are determined by screening differential molecules through enrichment analysis and PCR verification, accurate identification of a related gene system is achieved, and the problems of missing detection and insufficient accuracy caused by lack of transcriptome sequencing in a traditional method are solved.

The present disclosure provides bovine animals and methods to create recipient bovine animals for spermatogenic stem cell transplantation / complementation through modulation of the NANOS2 gene. In one embodiment genome editing was used to create bovine animals with insertions or deletions (indels) that inactivate or otherwise modulate NANOS2 gene activity so that resulting male bovines lack functional germ cells yet retain functional testicular somatic cells, and bovine females are fertile. These bovine males can then be transplanted or complemented with donor cells capable of giving rise to cells of the spermatogenic lineage, or spermatogenic stem cells and used for breeding.

The application discloses an immunogen for preparing testis-specific glyceraldehyde-3-phosphate dehydrogenase lysine malonylation site-specific antibody, and belongs to the technical field of biotechnology.The immunogen is a malonylation modified polypeptide, and the amino acid sequence is IIPASTGAAKAVT, corresponding to the 278th-290th amino acid of a human GAPDHS protein, wherein a lysine at the 287th position (the 10th position in the sequence) is subjected to malonylation modification.A specific antibody designed according to the immunogen has the characteristics of high titer and high specificity. By screening a human sperm sample by using the antibody, it is found that the antibody can not only specifically recognize the GAPDHS with the lysine at the 287th position subjected to malonylation modification in vitro and in human sperm, but also is closely related to sperm forward movement and asthenozoospermia. The application has great significance in the field of preparation of reagents for precision diagnosis and treatment of idiopathic male infertility.

This invention discloses a Fam205a1 Methods for constructing and applying gene knockout mouse models. The construction method utilizes CRISPR / Cas9 gene editing technology, targeting mice. Fam205a1 Gene-designed specific sgRNAs for knockout Fam205a1 The regions of exons 1 through 4 of the gene are obtained. Fam205a1 Gene knockout mice. Male mice in this model exhibit infertility, specifically characterized by impaired spermatogenesis, reduced sperm motility, abnormal sperm morphology (particularly head and acrosome defects), and spermatogenic cell apoptosis. However, the weight and appearance of their testes and epididymis show no significant difference from the wild type. The mouse model constructed in this invention has stable genetic traits and a well-defined phenotype, making it an ideal animal model for studying the mechanisms of idiopathic male infertility, screening drugs for treating male infertility, or developing male contraceptives.

The invention relates to the technical field of genetic engineering, in particular to application of PCK1 in preparation of products for regulating and controlling goat testicular interstitial cell proliferation. According to the invention, an over-expression plasmid pcDNA3.1 (+)-PCK1 of the PCK1 gene is constructed, an interference sequence si-PCK1 of the PCK1 gene is synthesized, and it is proposed for the first time that the over-expression of the PCK1 gene can significantly promote the proliferation of goat testicular interstitial cells, and the inhibition of the expression of the PCK1 gene can significantly inhibit the proliferation of the goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the PCK1 gene as the target spot.

An embodiment relates to polydeoxyribonucleotide (PDRN)-containing exosomes, a composition including same, and a preparation method therefor, wherein the PDRN-containing exosomes of the embodiment are derived from a fish testis tissue and include high-purity, low-molecular weight PDRN. In addition, exosomes containing a significant amount of low molecular weight PDRN can be induced through a simple process of ultrasonic treatment. Furthermore, application of ultrasound to the separated exosomes can prepare PDRN exosomes that are made to have low molecular weights, whereby the exosomes exhibit high intracellular uptake rates and thus can be advantageously used for manufacturing a tissue regeneration or anti-inflammatory composition.

The invention discloses preparation and application of a mouse TMC5 truncated recombinant protein and a polyclonal antibody, and belongs to the technical field of biological medicine. The amino acid sequence of the TMC5 truncated recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the TMC5 truncated recombinant protein is as shown in SEQ ID NO. 2. Compared with a full-length protein, the mouse TMC5 truncated recombinant protein provided by the invention has better stability and antigenicity, the obtained polyclonal antibody is high in titer and strong in specificity, the identification of endogenous TMC5 protein in mouse testicular tissues is facilitated, meanwhile, the TMC5 truncated recombinant protein and the polyclonal antibody can also be used for researching a mechanism of regulating spermatogenesis by TMC5, and the application prospect is broad. The blank of preparation of the mouse TMC5 antibody and functional research of the mouse TMC5 antibody in the testis is filled. The mouse TMC5 truncated recombinant protein and the polyclonal antibody can be applied to development of novel diagnostic reagents and drugs for treating male sterility.

The invention relates to the technical field of biological medicines, and discloses an application of a plant extract composition in preparation of a medicine for improving DNA damage of testicular spermatogenic cells, and the plant extract contains a herba epimedii extract and a rhizoma polygonati extract. The invention provides new application of the composition containing the herba epimedii extract and the rhizoma polygonati extract in preparation of the medicine for improving DNA damage of the testicular spermatogenic cells, the composition can remarkably improve the DNA damage of the testicular spermatogenic cells of mice caused by cyclophosphamide, recover the multiplication capacity of the mice, inhibit apoptosis of the mice and relieve spermatogenic function damage caused by cyclophosphamide, and the composition can be used for preparing the medicine for improving the DNA damage of the testicular spermatogenic cells of the mice. And the combined administration shows a synergistic effect instead of a simple additive effect, and the drug effect is obviously superior to that of any one of the epimedium extract and the rhizoma polygonati extract which are independently administered.

The invention discloses a construction method and application of a mouse model for testicular development disorder caused by Map3k1 gene mutation. The method comprises the following steps: designing and constructing sgRNA and a homologous recombinant vector capable of specifically recognizing a Map3k1 gene on the basis of a CRISPR / Cas9 system, injecting the sgRNA and the homologous recombinant vector into a mouse fertilized egg, screening out an F0-generation mouse with Map3k1 gene mutation from a mouse produced after the fertilized egg is transplanted, and hybridizing the F0-generation mouse with a wild type mouse to obtain a stably inherited Map3k1 gene mutation mouse model. The phenotype detection result of the mouse model shows that the fertility of the mouse model is remarkably reduced, and testis dysplasia conforms to the disease phenotype of testis dysplasia. The mouse model provides a convenient, reliable and economic means for researching the relationship between Map3k1 gene mutation and testicular dysplasia and the pathogenesis of the Map3k1 gene mutation and testicular dysplasia, and can be used for researching the pathogenesis of testicular dysplasia, a treatment method, drug screening and the like.

The invention belongs to the technical field of biotechnology and medicine, and particularly relates to application of an Anapc11 gene / protein to screening of drugs for treating hyperuricemia-related multi-organ dysfunction. According to the invention, the Anapc11 gene is used as a molecular target or a drug action target, and is used for screening or preparing drugs for treating multi-organ dysfunction (including liver injury, testis dysfunction, intestinal barrier destruction and the like) caused by hyperuricemia. The invention provides a new application of the cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, and breaks through the limitation that the existing uric acid reducing medicine is only limited to a metabolic link; a new direction and a good application prospect are provided for developing innovative medicines with organ protection effects.

The invention relates to the technical field of biological medicines, in particular to a medicine for improving aging-related metabolic obesity. According to the composition for reducing the expression level of the C2orf74 gene provided by the invention, the composition for reducing the expression level of the C2orf74 gene is used for preparing the medicine for improving senescence-related metabolic obesity, and the composition for reducing the expression level of the C2orf74 gene is injected into the testis of an animal in situ, so that the phenotype of obesity caused by senescence can be improved; the composition specifically comprises the following steps: reducing the weight increase, reducing the fat accumulation, reducing the levels of triglyceride and cholesterol in serum, improving the blood sugar regulation capability and enhancing the insulin sensitivity; the fatty liver degeneration degree is reduced.

The invention relates to the technical field of genetic engineering, in particular to application of miR-145-3p as a target spot in preparation of products for regulating and controlling proliferation of goat testicular interstitial cells. According to the invention, Inhibitor and Mimics sequences taking the miR-145-3p gene as a target spot are constructed, and it is proposed for the first time that overexpression of the miR-145-3p gene can significantly inhibit proliferation of goat testicular interstitial cells, and inhibition of the miR-145-3p gene can significantly promote proliferation of goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the miR-145-3p gene as a target spot.

The invention relates to application of PDCD5 in preparation of a diagnostic agent or a therapeutic agent for asthenospermia. The invention also discloses a method for constructing an asthenospermia mouse model or inhibiting fibroblast cilia generation by knocking out or knocking down the PDCD5. The application shows that PDCD5 participates in sperm generation, and asthenozoospermia can be caused if the PDCD5 has function deletion mutation in testis. Therefore, the gene locus can be used as a target spot for asthenospermia diagnosis and medication guidance. According to the method disclosed by the invention, the dysfunction of the site is supplemented by the PDCD5 RNA wrapped by the testis injection liposome, so that the asthenospermia caused by the mutation is rescued, the sperm quantity is increased, the sperm malformation rate is reduced, and a new path is provided for the treatment of the asthenospermia.

The present application provides use of compounds represented by formula (I) and formula (II) in the preparation of drugs for improving male reproductive ability. In the present application, different oligoasthenospermia models are constructed, and the improvement effects of the compounds represented by formula (I) and formula (II) on male reproductive ability impairment are verified by means of sperm count analysis, sperm motility analysis, mRNA expression level analysis of inflammatory and antioxidant genes, testicular histopathological damage analysis, etc. The experimental results show that the compounds represented by formula (I) and formula (II) increase the sperm count in mice with oligoasthenospermia, improve the sperm motility of the mice with oligoasthenospermia, ameliorate testicular histopathological damage in the mice, suppress the expression of inflammatory factors, and increase the expression of antioxidant genes, demonstrating great potential in the treatment of oligoasthenospermia.

This invention discloses the application of Polygonatum oligosaccharides in the preparation of products that improve sperm motility. The molecular weight of the Polygonatum oligosaccharides is 1 × 10⁻⁶. 4 ~5×10 4 This oligosaccharide, Da, can be prepared through steps including ethanol defatting, water extraction, 30%-50% ethanol precipitation, and protein removal. Experiments show that this oligosaccharide can significantly improve sperm motility, particularly restoring the forward sperm motility rate in asthenospermia model mice to over 32%, reaching the clinical treatment threshold; it can also effectively alleviate cyclophosphamide-induced reproductive damage and improve testicular tissue pathological damage. Furthermore, this oligosaccharide can upregulate the expression of sperm motility-related genes such as Crisp2 and Catsper, downregulate miR-27 expression, and has multiple effects including reducing oxidative stress, inhibiting inflammation, and improving reproductive hormone levels. Therefore, this oligosaccharide can be used to prepare products that improve sperm motility, prevent and / or treat asthenospermia, and alleviate chemotherapy-related reproductive damage.

The invention discloses a construction method of a Dcaf17 gene modified golden hamster model and application of the Dcaf17 gene modified golden hamster model. The method comprises the following steps: under a red light source, injecting a Cas9 functional element and sgRNA of a targeted Dcaf17 gene exon 1 through a two-cell embryo, and transplanting the embryo into a receptor body, so as to obtain the Dcaf17 gene modified golden hamster. The Dcaf17 gene modified golden hamster model is constructed by utilizing two-cell stage embryo gene editing, and the Dcaf17 gene modified golden hamster homozygous male rat has the phenotype characteristics of no fertilization ability, normal testis and the like, and is used for replacing ligation male rats to prepare false pregnancy receptor rats. The receptor can efficiently identify and utilize a false pregnancy receptor through microscopic examination of sperms by a microscope. Therefore, the invention solves the technical difficulty of receptor preparation in related experiments of assisted reproduction of the golden hamster, and can be used for phenotype research of the Dcaf17 gene and related applications of assisted reproduction of the golden hamster.

This invention relates to the field of biotechnology and discloses the application of mutated gene sites in altering the virulence and / or testicular adaptation of Zika virus. This invention innovatively discovers testicular adaptation sites and novel virulence sites in Zika virus. Mutating these functional sites can yield Zika virus mutant strains with altered virulence and / or testicular adaptation, which is of great significance for Zika virus research, the construction of related animal models, and drug development.